Healthcare and Diagnostics Market
15 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by victoria ernest
Scoop.it!

Organic Trace Minerals for Animal Feed Market Expected Growth Worldwide by 201

Organic Trace Minerals for Animal Feed Market Expected Growth Worldwide by 201 | Healthcare and Diagnostics Market | Scoop.it

Analysts forecast the Global Organic Trace Minerals for Animal Feed market to grow at a CAGR of 7.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the higher bioavailability of organic trace minerals than inorganic counterparts. The Global Organic Trace Minerals for Animal Feed market has also been witnessing the increasing usage in poultry layer diets. However, the higher R&D costs than inorganic trace minerals could pose a challenge to the growth of this market.

Global Organic Trace Minerals for Animal Feed Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, North America, and ROW; it also covers the Global Organic Trace Minerals for Animal Feed market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space include Alltech Inc., Balchem Corp., Kemin Industries Inc., Novus International Inc., Pancosma S.A., and Zinpro Corp.

Other vendors mentioned in the report are Albion Laboratories Inc., Aliphos, Global Animal Products Inc., Norel S.A., Phibro Animal Health Corp., Premex Inc., Priya Chemicals, QualiTech Corp., Suboneyo Chemicals Pharmaceuticals Ltd., Tank Biosciences Corp., Vamso Biotec Pvt. Ltd., Vetco (India) Pvt Ltd., and Wuhan Pharma Chemical Co. Ltd.

 

Inquire Before buying the Report @ http://www.sandlerresearch.org/inquire-before-buying?rname=14866 .

 

Key questions answered in this report:

What will the market size be in 2018 and what will be the growth rate?

What are key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by key vendors?

What are the strengths and weaknesses of each of these key vendors?

TechNavio’s analysts forecast the Global Organic Trace Minerals for Animal Feed market to grow at a CAGR of 7.58 percent over the period 2013-2018. One of the key factors contributing to this ma...
more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018 14864 - Sandler Research

Analysts forecast the Global Isothermal Nucleic Acid Amplification Technologies market will grow at a CAGR of 17.49 percent over the period 2013-2018. One of the key factors contributing to this market growth is the technological advances being made in this domain. The Global Isothermal Nucleic Acid Amplification Technologies market has also been witnessing an increase in the miniaturization of nucleic acid-based diagnostics. However, the tough competition from PCR-based diagnostics could pose a challenge to the growth of this market.

Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA region, and the APAC region; it also covers the Global Isothermal Nucleic Acid Amplification Technologies market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Corp.

The other vendors mentioned in the report are Alere Inc., Axxin Pvt Ltd., Eiken Chemical Co. Ltd., Great Basin Corp., Lucigen Corp., Meridian Bioscience Inc., New England Biolabs Inc., and Optigene Ltd.

 

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Newer Oral Anti Androgens: Prostate Cancer Paradigm Treatment Overvie

[44 Pages Report] Check for Discount on Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the treatment Paradigm of Prostate Cancer report by MP Advisors. XTANDI (Enzalutamide) – Does it have potential to comp...
victoria ernest's insight:

XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting?

Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry

In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide, Astellas/Medivation), Zytiga (Abiraterone acetate, JNJ), Jevtana (Cabazitaxel, Sanofi), & Xofigo (radium Ra 223, Boehringer Ingelheim) has evolved the treatment paradigm of treating late stage prostate cancer. In coming years, we expect this to repeat in early stage prostate cancer treatment (nmCRPC, before Prostectomy) due to launch of newer antiandrogens in this setting.  Longer duration of therapy and high prevalence makes this earlier setting market more lucrative and bigger for newer options than late stage if they succeed.

In coming years, we expect second generation antiandrogens (Androgen synthesis inhibitors/Androgen receptor inhibitors, Xtandi, ARN-509, ODM-021, Zytiga, TAK-700, TOK-001) to replace them and expand their use beyond current levels in nmCRPC (non metastatic Castrate resistance Prostate cancer) patients and also in pre-prostectomy (Chart 3).  This newer agents will expand these markets atleast by $10b ($6b in pre prostectomy, $4b nmCRPC) if get success.

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Oral & Injectable Drug Market Formulations for Pharma And Specialty Companie

Oral & Injectable Drug Market Formulations for Pharma And Specialty Companie | Healthcare and Diagnostics Market | Scoop.it

There are more than 1400 sustained or controlled release drugs have been approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall international pharmaceutical market. The utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.

The oral drug delivery market remains the largest slice of the overall drug delivery market, with more than 52% of the market share. It is presently valued at $49 billion and is expected to reach over $90 billion by 2016, at a CAGR of 11%. The growth in the oral drug delivery market shall be driven primarily by newer technologies enabling controlled release formulations of oral drugs and oral formulations of injectable only drugs. Global injectable drug delivery market is expected to be worth $29b by 2015.

Novel drug delivery systems (NDDS) offers many more advantages, which include improved therapy by increasing the efficacy and duration of drug activity, increased patient compliance through decreased dosing frequency and convenient routes of administration and improved targeting for a specific site to reduce unwanted side effects. The challenge for both drug and drug delivery companies is to deliver both existing and emerging drug technologies in a manner that improves the benefits to the patients.

 

Request Sample for this Report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=275193 .

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Global Hospital Information Systems (HIS) Market 2014-2018 13866 - Sandler Research

Global Hospital Information Systems (HIS) Market 2014-2018 13866 - Sandler Research | Healthcare and Diagnostics Market | Scoop.it

Global Hospital Information Systems (HIS) market to grow at a CAGR of 12.56 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increased demand for advanced health monitoring systems. The Global HIS market has also been witnessing the increased adoption of mobile devices. However, the lack of experienced professionals could pose a challenge to the growth of this market.

Global HIS Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HIS market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space are Cerner Corp., Epic Systems Corp., McKesson Corp., and Siemens Healthcare Ltd.

Other vendors mentioned in the report are Agfa Healthcare Corp., Allscripts, Healthcare Solutions Inc., Computer Program and Systems Inc., CompuGroup Medical AG, GE Healthcare, MEDHOST Solutions Corp. (Healthcare Management Systems Inc.), iSOFT Group plc/ Computer Sciences Corp., Keane Care Inc. (NTT Data Corp.), Medical Information Technology Inc. (MEDITECH), NextGen Healthcare Information Systems LLC, and QuadraMed.

 

 

Key questions answered in this report:

What will the market size be in 2018 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

 

 

 

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Prenatal Testing Market in the US 2014-2018 13841 - Sandler Research

Prenatal Testing Market in the US 2014-2018 13841 - Sandler Research | Healthcare and Diagnostics Market | Scoop.it

 

Analysts forecast the Prenatal Testing market in the US to grow at a CAGR of 5.43 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of fetal health-related abnormalities. The Prenatal Testing market in the US has also been witnessing the significant increase in the launch of new tests. However, the falling fertility rates in the US could pose a challenge to the growth of this market.

Prenatal Testing Market in the US 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report focuses on the US; it also covers the Prenatal Testing market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space are PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Inc.

Other vendors mentioned in the report are ANGLE plc, Ariosa Diagnostics Inc., BGI Health, CellScape Corp., Fluidigm Corp., Ikonisys Inc., Kellbenx Inc., Natera Inc., Ravgen Inc., and Trovagene Inc.

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

IBM Community Webcast Replay - XPages: A Remedy for the Healthcare Industry

Today's webcast attendees were treated to some inspiring examples of how XPages can be used in incredibly practical and important ways. Our main speakers wer...
more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Global Patient Temperature Management Market 2014-2018 14865 - Sandler Research

Global Patient Temperature Management Market 2014-2018 14865 - Sandler Research | Healthcare and Diagnostics Market | Scoop.it

Analysts forecast the Global Patient Temperature Management market to grow at a CAGR of 7.4 percent over the period 2013-2018. One of the key factors contributing to this market’s growth is the increasing incidence of cardiac and CNS disorders. The Global Patient Temperature Management market has also been witnessing an increase in mergers and acquisitions among the leading vendors to increase their global presence and to achieve economies of scale. However, the unavailability of adequate scientific support for the systematic and protocol-driven application of these devices could pose a challenge to the growth of this market.

Global Patient Temperature Management Market 2014-2018, has been prepared based on in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Patient Temperature Management market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space include 3M Health Care, Cincinnati Sub-Zero Products Inc., Covidien plc, Smiths Medical, and Stryker Corp.

Other vendors mentioned in the report are Augustine Temperature Management LLC, Belmont Instrument Corp., C. R. Bard Inc., Ecolab Inc., EMIT Corp., Enthermics Medical Systems Inc., GE Healthcare Ltd., Geratherm Medical AG, Philips Healthcare, Pintler Medical LLC, The 37 Co., WElkins LLC, ZOLL Medical Corp.

 

Inquire Before buying the Report @ http://www.sandlerresearch.org/inquire-before-buying?rname=14865 .

 

Key questions answered in this report:

What will the market size be in 2018 and what will be the growth rate?

What are the key market trends?

What is driving this market?

What are the challenges to the market’s growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by key vendors?

What are the strengths and weaknesses of each of these key vendors?

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Therapeutic Class Overview: Treating Refractory Hematological Malignancies : ReportsnReports

 

 

victoria ernest's insight:

Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes.  Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs – Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting in improved survival.  However, eventually all patients relapse and new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) are required to further improve survival and quality of life of this group of pts.  Two new drugs have successfully fulfilled this need – POMALYST/ IMNOVID (pomalidomide – POM) and Kyprolis (carfilzomib-CFZ) but is there room for more?

We expect a similar scenario to unfold in the treatment of Recurrent/ Refractory MDS (RR-MDS, High-Risk MDS), and Relapsed/ Refractory AML (R/R AML).  Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium.  The report provides an overview of the approved therapies for RRMM, NDMM, AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts.  The report highlights the competition and commercial opportunity in pursuing these therapy areas – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Emergence Of Biogenerics Era In Japan: Antibody Biosimilars of Foreign Origins

With three products and eight players already in market – Japan biosimilar market will enter new phase of biosimilars with first ‘mab’ approval expected in 2014.  This approval (Remicade- FY03/13A sales ¥73.5, infiximab from Nippon Kayaku by YE 14) will be marked as a milestone development because – 1.) it will open antibody biosimilar market in Japan, and 2.) the approval will be based largely from overseas data.

~ ¥200b worth of biologic products is going off patent by 2015 and this value exceeds ~ ¥400b if we include products that will see their patent expiries by 2021 in Japan (Table 1).   There are number of reasons to believe that follow-on-biologics or biosimilars will not replicate the lethargic growth story of generic – preliminary because the much higher cost of biologic therapy brings significant burden on patients despite relatively low co-pay in Japan – and this will push individuals and DPC Hospitals to use biogeneric products to a greater extent unlike generic drugs.  Secondly, the regulatory supports are going to be stringent enough to ensure quality measures and minimizing the ‘not made in Japan’ factor from prescriber’s and user’s mindsets.

Anticipating this opportunity and favorable macro forces as compared to generics, a number of companies aim to exploit this – Japan has seen a flood like consolidation and partnering activities in biosimilar space (Table 2, Annexure I).  While a dozen+ companies have already laid their road map for biosimilars space, at this time we see Sandoz, JCR, Meiji Seika Pharma, Fuji Film Kyowa Kirin Biologics, Nippon Kayaku, Nichi Iko, Yoshindo etc. to be amongst the key players in biogenerics business in Japan.

It is also noteworthy that large global player, which currently look silent in Japan.

In this piece, we attempt to evaluate the future competitive landscape  (Table 3) of the Biosimilars space in Japan, assess the overall attractiveness of the same, and try to identify the key determinates to succeed in this space.  At this point, we do not arrive at any investment recommendations from the sector

 

 

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradig

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life.  Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients.  The lack of targeted immune therapies other than TNF-α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc).  Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics.  In the last couple of years, the face of healthcare has been changing due to challenges – quality and its affordability and accessibility to the providers and patients.

We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards.  In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!

 

Request Sample for this Report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=275192 .

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Global Osteoporosis Drugs Market 2014-201

Global Osteoporosis Drugs Market 2014-201 | Healthcare and Diagnostics Market | Scoop.it

Analysts forecast the Global Osteoporosis Medicines market to grow at a CAGR of 3.98 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Osteoporosis Medicines market has also been witnessing the increasing awareness of bone health education. However, the multiple patent expiries could pose a challenge to the growth of this market.

Global Osteoporosis Medicines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Osteoporosis Medicines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space are Amgen Inc., Eli Lilly & Co., Merck & Co. Inc., and Novartis AG.

Other vendors mentioned in the report are Abiogen Pharma SpA, F. Hoffmann La Roche Ltd., GlaxoSmithKline plc, Ligand Pharmaceuticals Inc., NPS Pharma Inc., and Pfizer Inc.

more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Randox Laboratories -- clinical diagnostics equipment for medical healthcare

Randox is an international clinical diagnostic solutions company with sales and distribution agreements in 130 countries. Established in 1982, Randox have ca...
more...
No comment yet.
Scooped by victoria ernest
Scoop.it!

Use of Technology & Innovation in the Indian Healthcare Industry #TiESummit

Session Highlights 1. 80% of India's doctors live in urban cities. 2. There are roughly 12000000 blind people in India. Most of them can be cured through t...
more...
No comment yet.